Zubair Malik, MD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University and Director of the Esophageal Program at Temple University Hospital, offered his thoughts to Healio Gastroenterology about the U.S. Food and Drug Administration’s reintroduction of tegaserod (Zelnorm), a twice-daily oral treatment for irritable bowel syndrome with constipation, for women younger than 65.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH